We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

83 hedge funds and large institutions have $4.79M invested in VistaGen Therapeutics in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

1% more capital invested

Capital invested by funds: $4.75M → $4.79M (+$38.4K)

0.07% less ownership

Funds ownership: 0.66% → 0.58% (-0.07%)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 85 → 83 (-2)

Holders
83
Holders Change
-2
Holders Change %
-2.35%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
24
Reduced
18
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$163K
2
State Street
State Street
Massachusetts
+$47.1K
3
Allspring Global Investments
Allspring Global Investments
North Carolina
+$37.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$36.4K
5
HNWA
Henrickson Nauta Wealth Advisors
Michigan
+$35K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$668K
2
N
Nuveen
North Carolina
-$597K
3
Two Sigma Investments
Two Sigma Investments
New York
-$57.6K
4
Citadel Advisors
Citadel Advisors
Florida
-$37K
5
Morgan Stanley
Morgan Stanley
New York
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$15K +$6.69K +1,276 +47%
CAPTRUST Financial Advisors
27
CAPTRUST Financial Advisors
North Carolina
$13.6K +$19.1K +3,640 New
Barclays
28
Barclays
United Kingdom
$13.1K +$8.66K +1,652 +89%
Parallax Volatility Advisers
29
Parallax Volatility Advisers
California
$13.1K – – –
TRCT
30
Tower Research Capital (TRC)
New York
$13K +$4.12K +785 +28%
AIG
31
American International Group
New York
$12.5K +$346 +66 +2%
Group One Trading
32
Group One Trading
Illinois
$12.3K -$6.26K -1,194 -27%
Goldman Sachs
33
Goldman Sachs
New York
$12.2K -$2.62K -499 -13%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$12K +$9.84K +1,876 +141%
PLU
35
Performa Ltd (US)
South Carolina
$11.2K +$3.5K +667 +29%
Bank of America
36
Bank of America
North Carolina
$10.2K -$7.42K -1,416 -34%
SG Americas Securities
37
SG Americas Securities
New York
$10K +$10.6K +2,012 +284%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$9.6K -$991 -189 -7%
Invesco
39
Invesco
Georgia
$9.57K +$1.57K +300 +13%
Fidelity Investments
40
Fidelity Investments
Massachusetts
$9.02K +$7.06K +1,346 +126%
Neuberger Berman Group
41
Neuberger Berman Group
New York
$8.42K +$11.8K +2,251 New
DADC
42
D.A. Davidson & Co
Montana
$8.29K – – –
ACM
43
Advisors Capital Management
New Jersey
$8K – – –
MGIA
44
Moneta Group Investment Advisors
Missouri
$6.32K +$8.86K +1,689 New
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$5K – – –
TSS
46
Two Sigma Securities
New York
$4.36K -$2.09K -398 -25%
Osaic Holdings
47
Osaic Holdings
Arizona
$4.29K – – –
AB
48
Amalgamated Bank
New York
$4K +$288 +55 +6%
GSIAS
49
Garden State Investment Advisory Services
New Jersey
$3.74K – – –
Empower Advisory Group
50
Empower Advisory Group
Colorado
$3.58K +$4.74K +903 New
1
2
3 4

VTGN Hedge Fund Activity: Q1 2023 in Review

83 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2023, worth a combined $4.79M — up 0.81% from $4.75M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of VTGN and 12 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 24 added.

The largest buyer was BlackRock, adding an estimated $163K. The largest seller was GSA Capital Partners, cutting an estimated $668K.

  • 83 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $4.79M of VistaGen Therapeutics stock for Q1 2023, up 0.81% quarter-over-quarter.
  • 12 funds opened new VistaGen Therapeutics positions in Q1 2023 and 13 closed out, a net change of -1 holder.
  • The largest VistaGen Therapeutics buyer in Q1 2023 was BlackRock, an estimated $163K added.
  • The largest VistaGen Therapeutics seller in Q1 2023 was GSA Capital Partners, an estimated $668K sold.

Based on aggregated 13F filings for Q1 2023.